Gaps in translation from trials to practice

Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation

Elaine M. Hylek, Darae Ko, Christina L. Cove

Research output: Contribution to journalReview article

38 Citations (Scopus)

Abstract

Worldwide there is a tremendous need for affordable anticoagulants that do not require monitoring. The advent of the non-warfarin oral anticoagulant drugs represents a major advance for stroke prevention in atrial fibrillation (AF). The objectives of this review are to 1) identify gaps in our current knowledge regarding use of these single target anticoagulant drugs; 2) outline the potential implications of these gaps for clinical practice, and thereby, 3) highlight areas of research to further optimise their use for stroke prevention in AF.

Original languageEnglish (US)
Pages (from-to)783-788
Number of pages6
JournalThrombosis and Haemostasis
Volume111
Issue number5
DOIs
StatePublished - Jan 1 2014

Fingerprint

Anticoagulants
Atrial Fibrillation
Stroke
Research
Professional Practice Gaps

Cite this

Gaps in translation from trials to practice : Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation. / Hylek, Elaine M.; Ko, Darae; Cove, Christina L.

In: Thrombosis and Haemostasis, Vol. 111, No. 5, 01.01.2014, p. 783-788.

Research output: Contribution to journalReview article

@article{57982b3c09ba47fdb88cf3c527ec91ce,
title = "Gaps in translation from trials to practice: Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation",
abstract = "Worldwide there is a tremendous need for affordable anticoagulants that do not require monitoring. The advent of the non-warfarin oral anticoagulant drugs represents a major advance for stroke prevention in atrial fibrillation (AF). The objectives of this review are to 1) identify gaps in our current knowledge regarding use of these single target anticoagulant drugs; 2) outline the potential implications of these gaps for clinical practice, and thereby, 3) highlight areas of research to further optimise their use for stroke prevention in AF.",
author = "Hylek, {Elaine M.} and Darae Ko and Cove, {Christina L.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1160/TH13-12-1032",
language = "English (US)",
volume = "111",
pages = "783--788",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "5",

}

TY - JOUR

T1 - Gaps in translation from trials to practice

T2 - Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation

AU - Hylek, Elaine M.

AU - Ko, Darae

AU - Cove, Christina L.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Worldwide there is a tremendous need for affordable anticoagulants that do not require monitoring. The advent of the non-warfarin oral anticoagulant drugs represents a major advance for stroke prevention in atrial fibrillation (AF). The objectives of this review are to 1) identify gaps in our current knowledge regarding use of these single target anticoagulant drugs; 2) outline the potential implications of these gaps for clinical practice, and thereby, 3) highlight areas of research to further optimise their use for stroke prevention in AF.

AB - Worldwide there is a tremendous need for affordable anticoagulants that do not require monitoring. The advent of the non-warfarin oral anticoagulant drugs represents a major advance for stroke prevention in atrial fibrillation (AF). The objectives of this review are to 1) identify gaps in our current knowledge regarding use of these single target anticoagulant drugs; 2) outline the potential implications of these gaps for clinical practice, and thereby, 3) highlight areas of research to further optimise their use for stroke prevention in AF.

UR - http://www.scopus.com/inward/record.url?scp=84899717079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899717079&partnerID=8YFLogxK

U2 - 10.1160/TH13-12-1032

DO - 10.1160/TH13-12-1032

M3 - Review article

VL - 111

SP - 783

EP - 788

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 5

ER -